Sign in Create account

SUDARSHAN PHARMA INDUSTRIES LIMITED

Chemicals · Chemicals & Petrochemicals

BSE: 543828
₹37.30
▼ -0.07 (-0.19%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
32/100
Weak
Valuation
0/100
Expensive
Momentum
44/100
Neutral

QVM read Mixed signals Quality Weak, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹931 Cr
PE (TTM)
36.9
Industry median 24.4 (189 companies)
Price to Book
6.0
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-8.0
Free Cash Flow
₹-71 Cr
as of March 31, 2026
Industry median ₹-0 Cr (238 companies)
EPS Growth (YoY)
66.67%
as of June 30, 2026
Industry median 39.08% (220 companies)
Net Profit Growth (TTM)
Data unavailable.
Operating Revenue Growth (TTM)
Data unavailable.
Profit Growth (YoY)
61.85%
as of June 30, 2026
Industry median 23.11% (213 companies)
Revenue Growth (YoY)
16.41%
as of June 30, 2026
Industry median 17.49% (205 companies)
Current Ratio
1.07
as of March 31, 2026
Industry median 1.87 (237 companies)
Debt to Equity
1.81
as of March 31, 2026
Industry median 0.16 (224 companies)
Interest Coverage
2.14
as of June 30, 2026
Industry median 8.97 (221 companies)
Net Margin
3.65%
as of June 30, 2026
Industry median 7.49% (212 companies)
Operating Margin (EBIT)
9.86%
as of June 30, 2026
Industry median 11.88% (214 companies)
Operating Margin (TTM)
8.60%
as of June 30, 2026
Industry median 9.75% (219 companies)
Return on Assets
3.70%
as of March 31, 2026
Industry median 4.33% (217 companies)
Return on Capital Employed
29.31%
as of March 31, 2026
Industry median 10.34% (218 companies)
Return on Equity
14.39%
as of March 31, 2026
Industry median 7.52% (219 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 5 met
  • No Quality score is Strong (70 or more)
  • No Debt to equity is below 0.5 (1.81)
  • No Return on equity is 15% or more (14.4%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

1 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (1.4% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.2%
Low 37.0000 · High 37.9600
1W return
-6.7%
Low 37.0000 · High 40.0000
1M return
-4.5%
Low 37.0000 · High 42.5000
52W return
-10.1%
Low 30.7000 · High 42.5000
Lifetime High ₹87.3700 (Sept. 11, 2023)
Lifetime Low ₹32.3000 (Aug. 10, 2026)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
38.0
10D
38.6
20D
39.6
50D
46.1
100D
54.9
200D
68.1

Delivery and volume

Day avg. delivery
80.0%
Week avg. delivery
84.4%
Month avg. delivery
91.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

37.42
Pivot
First resistance37.84
Second resistance38.38
Third resistance38.80
First support36.88
Second support36.46
Third support35.92
Day RSI33.5
Day MFI43.8
Day MACD-1.92
Day MACD signal-2.25

Beta

1M1.28
3M1.00
1Y1.00
3Y0.53

Price change analysis

↓ -4.5%
Over 1 Month
LowHigh
37.0042.50
↓ -10.1%
Over 3 Months
LowHigh
30.7042.50
↓ -10.1%
Over 6 Months
LowHigh
30.7042.50
↓ -10.1%
Over 1 Year
LowHigh
30.7042.50
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 36.9 (own history: 41.1–45.6)
Undervalued (below its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹166 Cr
Net profit (June 30, 2026)
₹6 Cr
Basic EPS (June 30, 2026)
₹0.2500

Ranks #89 of 221 in Chemicals & Petrochemicals by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter58.93%
  • FII/FPI19.38%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings increased from 57.39% to 58.93% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 19.95% to 19.38% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 78 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
11 Feb 2025 NORTH STAR OPPORTUNITIES FUND VCC-BULL VALUE INCORPORATED VCC SUB-FUND Bulk Buy 1,500,000 35.7300 BSE
1 Jan 2025 MANSI SHARE & STOCK ADVISORS PRIVATE LIMITED Bulk Sell 1,248,000 44.3500 BSE
1 Jan 2025 SETU SECURITIES PVT LTD Bulk Buy 1,248,000 44.3500 BSE
28 Nov 2024 CENTURY INDIA OPPORTUNITY FUND PC Bulk Buy 1,600,000 41.9700 BSE
25 Sep 2024 SAROJ GUPTA Bulk Sell 75,200 424.3500 BSE
25 Sep 2024 EPITOME TRADING AND INVESTMENTS Bulk Buy 134,400 424.3300 BSE
25 Sep 2024 BISHWANATH PRASAD AGRAWAL Bulk Buy 139,200 412.4100 BSE
25 Sep 2024 SAROJ GUPTA Bulk Buy 150,400 411.0000 BSE
25 Sep 2024 EPITOME TRADING AND INVESTMENTS Bulk Sell 153,600 421.9200 BSE
23 Sep 2024 EPITOME TRADING AND INVESTMENTS Bulk Sell 52,800 381.4800 BSE

All bulk and block deals →

Corporate Announcements

All 6 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 Insider Trading / SAST Sudarshan Pharma Industries Ltd - 543828 - Closure of Trading Window
28 Sep 2026 Company Update Sudarshan Pharma Industries Ltd - 543828 - Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
15 Sep 2026 Company Update Sudarshan Pharma Industries Ltd - 543828 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
9 Sep 2026 Insider Trading / SAST Sudarshan Pharma Industries Ltd - 543828 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
9 Sep 2026 Insider Trading / SAST Sudarshan Pharma Industries Ltd - 543828 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
5 Sep 2026 Company Update Sudarshan Pharma Industries Ltd - 543828 - Announcement under Regulation 30 (LODR)-Acquisition

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong revenue growth YoY (16.4%)

Weaknesses

  • Thin net profit margin (3.6%)
  • High financial leverage (Debt/Equity 1.81)

Opportunities

Data unavailable.

Threats

  • PE above 35 (36.9) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about SUDARSHAN PHARMA INDUSTRIES LIMITED

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.